Heat Biologics Inc HTBX shares were trading more than 50% higher Monday after the Durham, North, Carolina-based biopharma company said in an SEC filing that it has filed a provisional patent application that would apply its immune system activating technology for the treatment or prevention of COVID-19, the new coronavirus originating from Wuhan, China.
The company specializes in developing therapies to activate patients' immune systems against cancer.
Heat Biologics' pipeline consists of three product candidates that are being tested as combination therapies for treating cancer.
Its pipeline is focused on T-cell activation and co-stimulation, as well as dual-acting immunotherapies to offer the potential benefits of combination immunotherapy without the need for multiple, independent biologics.
Its lead product candidate HS-110 is in Phase 2 development along with Bristol-Myers Squibb Co's BMY Opdivo in non-small cell lung cancer.
Heat Biologics shares were spiking 59.15% higher to 53 cents at the time of publication.
Related Links:
The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off
GW Pharma's Epidiolex Label Expansion, EU Launch Key Growth Drivers In 2020
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
